129 Introduction: The use of molecular imaging using radiolabeled somatostatin analogs
has revolutionized the management of Neuroendocrine tumors (NETs). Recently 64 Copper …

Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs.
We have previously shown the clinical potential of 64Cu-DOTATATE in a small first-in …

1854 Objectives The gold standard for functional imaging of patients with neuroendocrine
tumors has for several years been the SPECT based tracer 111In-DTPA-Octreotide. We …

Several authors reported the superiority of 68Ga-DOTANOC PET/CT to conventional
imaging (CI) for the assessment of neuroendocrine tumors (NET). However, the detection of …

68Ga-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N′′, N′′′-tetraacetic acid-d-
Phe1-Tyr3-octreotide (DOTA-TOC) PET has proven its usefulness in the diagnosis of …

504 Background: In 2012 we introduced the somatostatin receptor imaging ligand 64 Cu-
DOTATATE. A potential benefit compared to SPECT tracers and 68 Ga-labeled PET tracers …

Methods: In this study, we have compared the results of both investigations in 36 patients
who have been enrolled for diagnosis or assessment of neuro endocrine tumors. 99m Tc …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

Studies demonstrate that the investigational 64Cu-DOTATATE radiopharmaceutical may
provide diagnostic and logistical benefits over available imaging agents for patients with …

68Ga-DOTATOC and 68Ga-DOTATATE are 2 radiolabeled somatostatin analogs for in vivo
diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure …